<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1981 the BFM group introduced a new treatment strategy for B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>A cytoreductive prephase (<z:chebi fb="0" ids="8382">prednisone</z:chebi>/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>) was followed by eight 5-day courses of chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Fractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) 0.5 g/m2 (24-hour infusion), and MTX intrathecally were administered at each course and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (ARA-C)/teniposide (VM-26) was given alternately with <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In study ALL-BFM-83, central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) chemotherapy was intensified by adding <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, while MTX/ARA-C was administered intraventricularly </plain></SENT>
<SENT sid="4" pm="."><plain>Therapy duration was reduced to six courses </plain></SENT>
<SENT sid="5" pm="."><plain>In study ALL-BFM-86, MTX 0.5 g/m2 was replaced by high-dose (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) MTX, 5 g/m2 (24-hour infusion), and MTX/ARA-C/<z:chebi fb="2" ids="8378">prednisolone</z:chebi> intrathecal therapy was introduced </plain></SENT>
<SENT sid="6" pm="."><plain>Doses of ARA-C and VM-26 were increased and fractionated, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> was partially replaced by ifosfamide, and <z:chebi fb="0" ids="28445">vincristine</z:chebi> was added </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> irradiation was 24 Gy for prevention and 30 Gy for overt disease in studies ALL-BFM-81 and -83, but was omitted in ALL-BFM-86 </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 87 patients were enrolled, 22 (8 CNS-positive) in study <z:hpo ids='HP_0000001'>All</z:hpo>-BFM-81, 24 (7 CNS-positive) in study ALL-BFM-83, and 41 (0 CNS-positive) in study ALL-BFM-86 </plain></SENT>
<SENT sid="9" pm="."><plain>The estimated 5-year duration of event-free survival (EFS) was 43% in study ALL-BFM 81, 50% in study ALL-BFM-83, and 78% in study ALL-BFM-86 (minimal follow-up, 25 months) </plain></SENT>
<SENT sid="10" pm="."><plain>Nineteen of 24 relapses occurred while on therapy or shortly thereafter </plain></SENT>
<SENT sid="11" pm="."><plain>In study ALL-BFM 81, the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> was the most frequent site of failure </plain></SENT>
<SENT sid="12" pm="."><plain>In ALL-BFM-83, there were no isolated <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapses, but more bone marrow (BM) relapses occurred </plain></SENT>
<SENT sid="13" pm="."><plain>In ALL-BFM-86, localized manifestations were the predominant site of failure, no isolated BM relapses occurred, and only one <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse was diagnosed </plain></SENT>
<SENT sid="14" pm="."><plain>No single parameter exerted a consistent influence on outcome with one exception </plain></SENT>
<SENT sid="15" pm="."><plain>The presence of <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> after the first two courses was correlated with an increased risk of therapy failure </plain></SENT>
<SENT sid="16" pm="."><plain>We conclude that an intensive, short-pulse therapy delivered within a 4-month period is highly effective in the treatment of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="17" pm="."><plain>In addition to fractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/ifosfamide, a 24-hour infusion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> MTX 5 g/m2 in conjunction with an i.th. therapy is an important component for prevention of both systemic and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapses </plain></SENT>
<SENT sid="18" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> irradiation is not needed for <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>-negative patients </plain></SENT>
</text></document>